Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Alnylam Pharmaceuticals (NQ: ALNY ) 273.91 +7.32 (+2.75%) Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Alnylam Pharmaceuticals < Previous 1 2 3 4 5 6 7 8 9 ... 15 16 Next > Avadel Pharmaceuticals Stock Sees RS Rating Jump to 82 August 06, 2024 On Tuesday, Avadel Pharmaceuticals stock received a positive adjustment to its Relative Strength (RS) Rating, from 76 to 82. Via Investor's Business Daily How Is The Market Feeling About Alnylam Pharmaceuticals? August 06, 2024 Via Benzinga DoorDash And Exact Sciences Are Among Top 10 Large Cap Gainers Last Week (July 28-Aug 3): Are The Others In Your Portfolio? August 04, 2024 Top 10 stocks with highest gains last week, including Exact Sciences, Alnylam Pharmaceuticals, Resmed, Coca-Cola Consolidated, DexCom, Sprouts Farmers Market, UL Solutions, Labcorp Holdings, C.H.... Via Benzinga Air Products Posts Upbeat Earnings, Joins Meta, Exact Sciences, Shake Shack, Clearwater Analytics And Other Big Stocks Moving Higher On Thursday August 01, 2024 Via Benzinga $100 Invested In This Stock 20 Years Ago Would Be Worth $4,100 Today July 18, 2024 Via Benzinga Peering Into Alnylam Pharmaceuticals's Recent Short Interest July 17, 2024 Via Benzinga Peering Into Alnylam Pharmaceuticals's Recent Short Interest June 27, 2024 Via Benzinga Alnylam Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Period Activity August 01, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst July 22, 2024 Ionis Pharmaceuticals releases positive results from Phase 1/2 study of ION582 for Angelman syndrome, showing consistent clinical improvements in communication, cognition, and motor function. Safety... Via Benzinga Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results July 18, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Alnylam Stock Is a Blockbuster Biopharma In the Making July 18, 2024 Alnylam stock could significantly pad its initial gains if vutrisiran gains expedited approval to hit the market. Via InvestorPlace 35% Surge Just the Beginning? Alnylam’s Stock Poised for Massive Gains on Heart Drug Success. July 11, 2024 Alnylam Pharmaceuticals stock recently popped and could continue to move higher on Alnylam Pharmaceuticals' cardiovascular drug announcement. Via InvestorPlace 7 Cheap Biotech Stocks With Major Upside Potential July 09, 2024 While the broader healthcare sector enjoys permanent relevance, you can potentially maximize your upside with cheap biotech stocks. Via InvestorPlace Down 55%, Is Pfizer a Good Dividend Stock to Buy on the Dip? July 08, 2024 Shares of the world's largest drugmaker offer a dividend yield above 6% at recent prices. Via The Motley Fool EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO July 07, 2024 The GLP-1 drug market for obesity treatment is expected to skyrocket to $1 trillion or more, according to Maurits Pot, founder and CEO of Tema ETFs. Via Benzinga Topics ETFs $100 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth This Much Today July 03, 2024 Via Benzinga Top Performing Industry ETFs In June: Software Leads Returns, Chipmakers Attract Most Inflows July 01, 2024 June saw gains in the U.S. stock market, with tech and biotech leading the way. Semiconductor ETFs saw strong inflows, while utilities lagged. Via Benzinga Topics ETFs 10 Health Care Stocks With Whale Alerts In Today's Session July 01, 2024 Via Benzinga Rivian Automotive And Carvana Were Among The 10 Biggest Large Cap Gainers Last Week (June 23-June 29): Are These In Your Portfolio? June 30, 2024 The top 10 large-cap stocks in the last week were RIVN, CUK, FDX, IOT, SUZ, CVNA, FTAI, RDDT, MDB, and ALNY. Many analysts have raised their price forecasts for these stocks. Via Benzinga 10 Health Care Stocks Whale Activity In Today's Session June 26, 2024 Via Benzinga Nvidia, Affirm Holdings, Carnival Corp, Alnylam Pharmaceuticals, Tesla: Why These 5 Stocks Are On Investors' Radars Today June 24, 2024 On Monday, major U.S. indices showed mixed performance. The Dow Jones Industrial Average closed up by nearly 0.7% at 39,411.21, Via Benzinga Topics Stocks Exposures US Equities Semiconductor, Nvidia Woes Deepen; Nasdaq 100 Slips, Dow Rallies; Bitcoin Sinks To $60,400: What's Driving Markets Monday? June 24, 2024 Wall Street faces a continuation of last week’s trend during Monday’s morning trading, with semiconductor stocks selling off heavily and dragging down the tech sector, while the broader market remains... Via Benzinga Topics Stocks Exposures US Equities Coffee Recall 2024: Over 250 Coffee Products Recalled Due to Botulism Fears June 24, 2024 A 2024 coffee recall is in effect for products made by Snapchill LLC due to concerns of botulism from the FDA for hundreds of canned coffees. Via InvestorPlace Exposures Product Safety Alnylam (ALNY) Stock Soars 30% on Heart Disease Drug Success June 24, 2024 The challenge for Alnylam now will be to find and diagnose patients with the condition known as ATTR-CM, which is considered rare. Via InvestorPlace Alnylam's Closely Watched Phase 3 Heart Disease Trial Of Vutrisiran Hits Primary Endpoint, Shares Surge June 24, 2024 Alnylam Pharmaceuticals reports positive results from the HELIOS-B Phase 3 study of vutrisiran for ATTR amyloidosis with cardiomyopathy. The trial showed significant reductions in mortality and... Via Benzinga Alnylam Skyrockets After Hitting A 'Best-Case Scenario' For Heart Drug June 24, 2024 The companies are working on treatments for ATTR amyloidosis with cardiomyopathy. Via Investor's Business Daily RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session June 24, 2024 Via Benzinga Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations June 24, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Masters In Trading - Saturday, June 22 June 22, 2024 In this video, I discuss a stock that is expected to see major upside, and I take a closer look at my portfolio. Via Talk Markets Here's How Much $1000 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth Today June 14, 2024 Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 ... 15 16 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
